|
1
|
Global Burden of Disease Liver Cancer
Collaboration, ; Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu
MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The
burden of primary liver cancer and underlying etiologies from 1990
to 2015 at the global, regional, and national level: Results from
the global burden of disease study 2015. JAMA Oncol. 3:1683–1691.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mavros MN, Mayo SC, Hyder O and Pawlik TM:
A systematic review: Treatment and prognosis of patients with
fibrolamellar hepatocellular carcinoma. J Am Coll Surg.
215:820–830. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan N, Zhu B, Shu H, Tao YF, Wu JR, Fang
M, Li CR, Chen ZQ and Ou C: Effect of lncRNA-BC200 on proliferation
and migration of liver cancer cells in vitro and in
vivo. Oncol Rep. 43:461–470. 2020.PubMed/NCBI
|
|
4
|
Stipa F, Yoon SS, Liau KH, Fong Y,
Jarnagin WR, DAngelica M, Abou-Alfa G, Blumgart LH and DeMatteo RP:
Outcome of patients with fibrolamellar hepatocellular carcinoma.
Cancer. 106:1331–1338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kakar S, Burgart LJ, Batts KP, Garcia J,
Jain D and Ferrell LD: Clinicopathologic features and survival in
fibrolamellar carcinoma: Comparison with conventional
hepatocellular carcinoma with and without cirrhosis. Mod Pathol.
18:1417–1423. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arun G, Diermeier SD and Spector DL:
Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol
Med. 24:257–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Feng W, Liu W, Kong X, Li L, He J,
Wang D, Zhang M, Zhou G, Xu W, et al: Circulating lncRNA ABHD11-AS1
serves as a biomarker for early pancreatic cancer diagnosis. J
Cancer. 10:3746–3756. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chi Y, Wang D, Wang J, Yu W and Yang J:
Long non-coding RNA in the pathogenesis of cancers. Cells.
8:10152019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong G, Wang K, Li J, Xiao S, Wei W and
Liu J: Determination of serum exosomal H19 as a noninvasive
biomarker for breast cancer diagnosis. Onco Targets Ther.
13:2563–2571. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu W, Zhou G, Wang H, Liu Y, Chen B, Chen
W, Lin C, Wu S, Gong A and Xu M: Circulating lncRNA SNHG11 as a
novel biomarker for early diagnosis and prognosis of colorectal
cancer. Int J Cancer. 146:2901–2912. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang G, Chi N, Lu Q, Zhu D and Zhuang Y:
LncRNA PTCSC3 is a biomarker for the treatment and prognosis of
gastric cancer. Cancer Biother Radiopharm. 35:77–81. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao Z, Zhang Y, Xu D, Zhou X, Peng P, Pan
Z, Xiao N, Yao J and Li Z: Research progress on long non-coding RNA
and radiotherapy. Med Sci Monit. 25:5757–5770. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan L, Zhang L, Fan K, Cheng ZX, Sun QC
and Wang JJ: Knockdown of long noncoding RNA PCAT6 inhibits
proliferation and invasion in lung cancer cells. Oncol Res.
24:161–170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bai F, Zhang N, Fang W, He X, Zheng Y and
Gu D: PCAT6 mediates cellular biological functions in
gastrointestinal stromal tumor via upregulation of PRDX5 and
activation of Wnt pathway. Mol Carcinog. 59:661–669. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang W, Su G, Huang X, Zou A, Wu J, Yang
Y, Zhu Y, Liang S, Li D, Ma F and Guo L: Long noncoding RNA PCAT6
inhibits colon cancer cell apoptosis by regulating anti-apoptotic
protein ARC expression via EZH2. Cell Cycle. 18:69–83. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu C, Huang L, Xu F, Li P, Li P and Hu F:
LncRNA PCAT6 promotes tumor progression in osteosarcoma via
activation of TGF-β pathway by sponging miR-185-5p. Biochem Biophys
Res Commun. 521:463–470. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang X, Feng D, Li M, Zhou J, Li X, Zhao
D, Hao B, Li D and Ding K: Transcriptomic analysis of
mRNA-lncRNA-miRNA interactions in hepatocellular carcinoma. Sci
Rep. 9:160962019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gnoni A, Santini D, Scartozzi M, Russo A,
Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V,
et al: Hepatocellular carcinoma treatment over sorafenib:
Epigenetics, microRNAs and microenvironment. Is there a light at
the end of the tunnel? Expert Opin Ther Targets. 19:1623–1635.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He S, Yang J, Jiang S, Li Y and Han X:
Circular RNA circ_0000517 regulates hepatocellular carcinoma
development via miR-326/IGF1R axis. Cancer Cell Int. 20:4042020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Council for International Organizations of
Medical Sciences (CIOMS), . International Ethical Guidelines for
Biomedical Research Involving Human Subjects. CIOMS; Geneva: pp.
p602002
|
|
22
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng J, Luo J, Zeng H, Guo L and Shao G:
125I suppressed the Warburg effect via regulating
miR-338/PFKL axis in hepatocellular carcinoma. Biomed Pharmacother.
119:1094022019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng H, Zheng J, Wen S, Luo J, Shao G and
Zhang Y: MicroRNA-339 inhibits human hepatocellular carcinoma
proliferation and invasion via targeting ZNF689. Drug Des Devel
Ther. 13:435–445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li HW and Liu J: Circ_0009910 promotes
proliferation and metastasis of hepatocellular carcinoma cells
through miR-335-5p/ROCK1 axis. Eur Rev Med Pharmacol Sci.
24:1725–1735. 2020.PubMed/NCBI
|
|
28
|
Liu Y and Shi SL: The roles of hnRNP A2/B1
in RNA biology and disease. Wiley Interdiscip Rev RNA.
12:e16122021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Zhang Y, Chen Y and Ding L:
Incidence trend of liver cancer: An analysis of 40 years data from
Qidong population-based cancer registry. Zhongguo Zhong Liu.
23:621–628. 2014.PubMed/NCBI
|
|
31
|
Sun Z, Chen T, Thorgeirsson SS, Zhan Q,
Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, et al: Dramatic
reduction of liver cancer incidence in young adults: 28 year
follow-up of etiological interventions in an endemic area of China.
Carcinogenesis. 34:1800–1805. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kondo Y, Shinjo K and Katsushima K: Long
non-coding RNAs as an epigenetic regulator in human cancers. Cancer
Sci. 108:1927–1933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Camacho CV, Choudhari R and Gadad SS: Long
noncoding RNAs and cancer, an overview. Steroids. 133:93–95. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun Y, Zhang F, Wang L, Song X, Jing J,
Zhang F, Yu S and Liu H: A five lncRNA signature for prognosis
prediction in hepatocellular carcinoma. Mol Med Rep. 19:5237–5250.
2019.PubMed/NCBI
|
|
35
|
Cai C, Yang L, Tang Y, Wang H, He Y, Jiang
H and Zhou K: Prediction of overall survival in gastric cancer
using a nine-lncRNA. DNA Cell Biol. 38:1005–1012. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wan L, Zhang L, Fan K and Wang JJ:
Diagnostic significance of circulating long noncoding RNA PCAT6 in
patients with non-small cell lung cancer. Onco Targets Ther.
10:5695–5702. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu
Q, Tong X, Yang W, Xu Q, Huang D and Tu K: A novel lncRNA
MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by
targeting miR-194-5p/FOXA1 axis. Mol Cancer. 18:282019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi X, Liu Z, Liu Z, Feng X, Hua F, Hu X,
Wang B, Lu K and Nie F: Long noncoding RNA PCAT6 functions as an
oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell
lung cancer. EBioMedicine. 37:177–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lv XJ, Tang Q, Tu YQ, Yan DD and Wei QC:
Long noncoding RNA PCAT6 regulates cell growth and metastasis via
Wnt/β-catenin pathway and is a prognosis marker in cervical cancer.
Eur Rev Med Pharmacol Sci. 23:1947–1956. 2019.PubMed/NCBI
|
|
41
|
Wu H, Zou Q, He H, Liang Y, Lei M, Zhou Q,
Fan D and Shen L: Long non-coding RNA PCAT6 targets miR-204 to
modulate the chemoresistance of colorectal cancer cells to
5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med.
8:2484–2495. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi R, Wu P, Liu M, Chen B and Cong L:
Knockdown of lncRNA PCAT6 enhances radiosensitivity in
triple-negative breast cancer cells by regulating miR-185-5p/TPD52
axis. Onco Targets Ther. 13:3025–3037. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lin C, Yuan G, Hu Z, Zeng Y, Qiu X, Yu H
and He S: Bioinformatics analysis of the interactions among lncRNA,
miRNA and mRNA expression, genetic mutations and epigenetic
modifications in hepatocellular carcinoma. Mol Med Rep.
19:1356–1364. 2019.PubMed/NCBI
|
|
44
|
Dong D, Lun Y, Sun B, Sun H, Wang Q, Yuan
G and Quan J: Silencing of long non-coding RNA PCAT6 restrains
gastric cancer cell proliferation and epithelial-mesenchymal
transition by targeting microRNA-15a. Gen Physiol Biophys. 39:1–12.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zou X, Zhong J, Li J, Su Z, Chen Y, Deng
W, Li Y, Lu S, Lin Y, Luo L, et al: miR-362-3p targets nemo-like
kinase and functions as a tumor suppressor in renal cancer cells.
Mol Med Rep. 13:994–1002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang D, Wang H, Li Y and Li Q: MiR-362-3p
functions as a tumor suppressor through targeting MCM5 in cervical
adenocarcinoma. Biosci Rep. 38:BSR201806682018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu M, Kong X, Wang H, Huang G, Ye C and He
Z: A novel microRNAs expression signature for hepatocellular
carcinoma diagnosis and prognosis. Oncotarget. 8:8775–8784. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hu S, Ran Y, Chen W, Zhang Y and Xu Y:
MicroRNA-326 inhibits cell proliferation and invasion, activating
apoptosis in hepatocellular carcinoma by directly targeting LIM and
SH3 protein 1. Oncol Rep. 38:1569–1578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mo Y, He L, Lai Z, Wan Z, Chen Q, Pan S,
Li L, Li D, Huang J, Xue F and Che S: Gold nano-particles (AuNPs)
carrying miR-326 targets PDK1/AKT/c-myc axis in hepatocellular
carcinoma. Artif Cells Nanomed Biotechnol. 47:2830–2837. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ma J, Wang T, Guo R, Yang X, Yin J, Yu J,
Xiang Q, Pan X, Tang H and Lei X: Involvement of miR-133a and
miR-326 in ADM resistance of HepG2 through modulating expression of
ABCC1. J Drug Target. 23:519–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Song W, Qian Y, Zhang MH, Wang H, Wen X,
Yang XZ and Dai WJ: The long non-coding RNA DDX11-AS1 facilitates
cell progression and oxaliplatin resistance via regulating
miR-326/IRS1 axis in gastric cancer. Eur Rev Med Pharmacol Sci.
24:3049–3061. 2020.PubMed/NCBI
|
|
52
|
Yu W, Peng W, Sha H and Li J:
Hsa_circ_0003998 promotes chemoresistance via modulation of miR-326
in lung adenocarcinoma cells. Oncol Res. 27:623–628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mizuno H, Honda M, Shirasaki T, Yamashita
T, Yamashita T, Mizukoshi E and Kaneko S: Heterogeneous nuclear
ribonucleoprotein A2/B1 in association with hTERT is a potential
biomarker for hepatocellular carcinoma. Liver Int. 32:1146–1155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang H, Liang L, Dong Q, Huan L, He J, Li
B, Yang C, Jin H, Wei L, Yu C, et al: Long noncoding RNA miR503HG,
a prognostic indicator, inhibits tumor metastasis by regulating the
HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma. Theranostics.
8:2814–2829. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang Y, Wei Q, Tang Y, Wang Y, Luo Q, Zhao
H, He M, Wang H, Zeng Q, Lu W, et al: Loss of hnRNPA2B1 inhibits
malignant capability and promotes apoptosis via down-regulating
Lin28B expression in ovarian cancer. Cancer Lett. 475:43–52. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shi X, Ran L, Liu Y, Zhong SH, Zhou PP,
Liao MX and Fang W: Knockdown of hnRNP A2/B1 inhibits cell
proliferation, invasion and cell cycle triggering apoptosis in
cervical cancer via PI3K/AKT signaling pathway. Oncol Rep.
39:939–950. 2018.PubMed/NCBI
|
